VISFATIN LEVEL DISTURBANCES IN PERIPHERAL BLOOD OF PATIENTS WITH DIABETIC NEPHROPATHY

  • I.I. Topchii SI «National Institute of Therapy named after L. Malaya of NAMS of Ukraine»
  • P.S. Semenovykh SI «National Institute of Therapy named after L. Malaya of NAMS of Ukraine»
  • V.YU. Galchinskaya SI «National Institute of Therapy named after L. Malaya of NAMS of Ukraine»
  • N.V. Yefimova SI «National Institute of Therapy named after L. Malaya of NAMS of Ukraine»
Keywords: diabetic nephropathy, visfatin, body mass index

Abstract

 Introduction. Recent studies suggest that visfatin participates in pathogenesis of vascular diabetic complications, in particular diabetic nephropathy (DN). The aim of the present research - definition of visfatin level in peripheral blood of type 2 diabetic patients taking to account renal function disturbances and body mass index (BMI).

Materials and methods. 94 type 2 diabetic patients with different stages of DN and 10 healthy subjects (control group) were observed. Visfatin concentration in blood plasma was determined using immunoassay kit.

Results. An essential increase of visfatin level in blood plasma took place already in initial stages of the DN. Progressing of the disease was accompanied by more expressed growth of visfatin concentration. In patients with high BMI substantial increase of visfatin level when compared with those with normal IMT was determined. We established strong correlations between visfatin concentrations, urinary albumin levels and blood creatinine concentrations and negative correlations with glomerular filtration rate.

Conclusions: Our findings testify that visfatin level displays a functional kidney state and may be used as addition to traditional methods of patients examination.

Downloads

Download data is not yet available.

References

Берштейн Л.М. Гормоны жировой ткани (адипоцитокины) / Берштейн Л.М. // Успехи геронтологии. – 2005. - №16. – С. 51-64.

Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions / Adeghate E. // Curr Med Chem. - 2008. - vol. 15. - P. 1851-1862.

Bessa S. S. Serum visfatin as a non-traditional biomarker of endothelial dysfunction in chronic kidney disease: an Egyptian study / S. S. Bessa, S. M. Hamdy, R. G. El- Sheikh // Eur J Intern Med. – 2010. – vol. 21(6). – Р. 530-535.

Guzik T. J. Adipocytokines - novel link between inflammation and vascular function. / T. J. Guzik, D. Mangalat, R. J. Korbut // Physiol Pharmacol . – 2006. – vol. 57. – Р. 505-528.

Huang Y. PAI-1 as a target in kidney disease. / Huang Y., Noble N.A. // Curr Drug Targets. 2007 – Vol. 8, № 9. –P.1007-1015.

Kang Y.S. Visfatin is upregulated in type-2 diabetic rats and targets renal cells / Y. S. Kang, H. K. Song, M. H. Lee // Kidney Int. – 2010. – vol.78. – Р.170-181.

Mahmood N. Association of visfatin with chronic kidney disease in a cohort of patients with and without diabetes / N. Mahmood, A. M. Junejo , Q. Jamal // J Pak Med Assoc. – 2010. – vol. 60. – Р. 922-926.

Moschen A. R. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties / A. R. Moschen, A. Kaser, B. Enrich // J Immunol. – 2007. - vol. 178(3). - Р. 1748-1758.

Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation / R. Adya, B. K. Tan, J. Chen [et al] // Diabetes Care. - 2008. - vol. 31(4). - Р.758-760.

SonoliS. S. Visfatin--a review / S. S. Sonoli, S. Shivprasad, C. V. Prasad [et al] // Eur Rev Med Pharmacol Sci. - 2011. - vol. 15(1). - P. 9-14.

Tesch G. H. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy / Tesch G. H. // Am J Physiol Renal Physiol. - 2008. - Vol.294. - P.697-701.

Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure / J. Malyszko, J. S. Malyszko, K. Pawlak [et al] // Adv Med Sci. - 2008. - vol. 53(1). - Р. 32-36.

Visfatin: a new player in mesangial cell physiology and diabetic nephropathy / H. K. Song, M.H. Lee, B.K. Kim [et al] // Am J Physiol Renal Physiol. – 2008. – vol. 295. - P. 1485-1494.

Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway / W. J Lee, C. S. Wu, H. Lin [et al] // Int J Obes (Lond). - 2009. - vol. 33(4). - Р. 465-472.

Yilmaz M. I. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin / M. I. Yilmaz, M. Saglam, A. R. Qureshi // Nephrol Dial Transplant. - 2008. - vol.23. - P.1621-1627.


Abstract views: 257
PDF Downloads: 161
Published
2014-12-12
How to Cite
Topchii, I., Semenovykh, P., Galchinskaya, V., & Yefimova, N. (2014). VISFATIN LEVEL DISTURBANCES IN PERIPHERAL BLOOD OF PATIENTS WITH DIABETIC NEPHROPATHY. Ukrainian Journal of Nephrology and Dialysis, (1(45), 25-30. https://doi.org/10.31450/ukrjnd.1(45).2015.05

Most read articles by the same author(s)